Exagen Inc（XGN）财务数据XGNExagen Inc

Exagen Inc. (XGN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial, accounting for 51.9% of total sales, equivalent to $10.35M. Other significant revenue streams include Government and Client. Understanding this composition is critical for investors evaluating how XGN navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Exagen Inc. maintains a gross margin of 61.27%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8.64%, while the net margin is -16.03%. These profitability ratios, combined with a Return on Equity (ROE) of -113.82%, provide a clear picture of how effectively XGN converts its operational activities into shareholder value.

In the context of the broader market, XGN competes directly with industry leaders such as BDSX and BNR. With a market capitalization of $206.20M, it holds a significant position in the sector. When comparing efficiency, XGN's gross margin of 61.27% stands against BDSX's 82.06% and BNR's 72.58%. Such benchmarking helps identify whether Exagen Inc. is trading at a premium or discount relative to its financial performance.

Exagen's revenue has shown consistent growth, with Q2 2026 revenue at $19.9 million, a 16% increase year-over-year. The gross margin improved to over 61%, reflecting effective cost management. However, the company continues to report net losses, with a net income of -$3.2 million in Q2 2026.